Nezu Life Science

Nezu Life Sciences is a Tokyo-based biotechnology company focused on developing small molecule therapeutics for rare genetic diseases caused by nonsense mutations. The company utilizes its proprietary TRID (Translational Read-through Inducing Drug) discovery platform to identify compounds that enable the ribosome to bypass premature termination codons (PTCs), thereby restoring the production of full-length, functional proteins. Their primary research efforts target high-unmet-need indications such as Duchenne muscular dystrophy and cystic fibrosis. By leveraging advanced screening and medicinal chemistry, Nezu aims to overcome the toxicity and efficacy limitations associated with first-generation read-through agents. The company is actively advancing its lead programs through pre-clinical development to address a wide range of genetic disorders.